Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ijcp.14016 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Ranolazine effects on exercise tolerance and angina frequency in Taiwanese stable angina: A bridging study of the CARISA randomized trial.
J Formos Med Assoc
October 2024
National Taiwan University Hospital, Taiwan. Electronic address:
Article Synopsis
- A study investigated the effectiveness of Ranolazine for chronic angina in a Taiwanese population, specifically those still experiencing symptoms despite conventional treatment.
- The research was a multi-center, randomized, double-blind trial, focusing on how much the exercise treadmill test (ETT) duration improved after 12 weeks of treatment with Ranolazine compared to a placebo.
- Results showed a significant increase in ETT duration for those receiving Ranolazine, with similar safety profiles to previous studies, indicating that adding Ranolazine could enhance exercise performance and tolerance in chronic angina patients.
Cost-utility of Ranolazine for Chronic Stable Angina Pectoris: Systematic Review and Meta-analysis.
Clin Ther
May 2023
Health Technology Assessment Resource Centre, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India. Electronic address:
Purpose: Ranolazine is used to treat stable angina pectoris, the most common symptom of ischemic heart disease. Appropriate management of chronic stable angina pectoris is essential from both a clinical and an economic view point.
Methods: This systematic review and meta-analysis adhered to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
Sodium channel blockers in the management of long QT syndrome types 3 and 2: A system review and meta-analysis.
J Cardiovasc Electrophysiol
November 2021
School of Clinical Medicine, Tsinghua University, Beijing, China.
Background: β-Blockers are first-line therapy in patients with long QT syndrome (LQTS). However, β-blockers had genotype dependent efficacy (LQT1>LQT2>LQT3). Sodium channel blockers have been recommended as add-on therapy for LQT3 patients.
View Article and Find Full Text PDFRole of Ranolazine in the Prevention and Treatment of Atrial Fibrillation in Patients with Left Ventricular Systolic Dysfunction: A Meta-Analysis of Randomized Clinical Trials.
Diseases
April 2021
Cardiac Center, Division of Cardiovascular Medicine, Department of Internal Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand.
Ranolazine has the potential to prevent atrial fibrillation (AF) and plays a role in rhythm control strategy for atrial fibrillation in various clinical settings. However, data on the use of ranolazine in patients with left ventricular (LV) systolic dysfunction are limited. The aims of this meta-analysis of randomized clinical trials are to investigate the efficacy and safety of ranolazine in AF patients with LV systolic dysfunction.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!